Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 12, 2014, Pages F1355-F1362

  Sasser, Jennifer M ^a,b   Cunningham, Mark W ^b   Baylis, Chris ^b,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dimethylarginine dimethylaminohydrolase; NADPH oxidase; Nitric oxide; Protein arginine methyltransferase 1

Indexed keywords

8 ISOPROSTANE; ANGIOTENSIN II; CITRULLINE; CREATININE; N(G),N(G) DIMETHYLARGININE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERELAXIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGININE; N,N-DIMETHYLARGININE; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; HYPERTENSION; KIDNEY CORTEX; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRESSOR RESPONSE; PROTEIN URINE LEVEL; PROTEINURIA; RAT; URINARY EXCRETION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ARTERIAL PRESSURE; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; HUMAN; KIDNEY; LIVER; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ARGININE; ARTERIAL PRESSURE; DINOPROST; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; KIDNEY; LIVER; MALE; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; PROTEINURIA; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RELAXIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84918793876     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00407.2014     Document Type: Article

References (33)

1. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 10: 3–9, 2005.
2. Bathgate RD, Halls ML, Van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev 93: 405–480, 2013.
3. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1–F9, 2008.
4. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285: R117–R124, 2003.
5. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88: 1559–1567, 1991.
6. Chow BSM, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES, Widdop RE, Summers RJ, Bathgate RAD, Hewitson TD, Samuel CS. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int 86: 75–85, 2014.
7. Danielson L, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 103: 525–533, 1999.
8. Fallowfield J, Hayden AL, Snowdon VK, Aucott RL, Stutchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Henke A, Schrader J, Trivedi PJ, Princivalle M, Forbes SJ, Collins JE, Iredale JP. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology 59: 1492–1504, 2014.
9. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, De Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45–51, 1997.
10. Hasegawa K, Wakino S, Tatematsu S, Yoshioka K, Homma K, Sugano N, Kimoto M, Hayashi K, Itoh H. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 101: e2–e10, 2007.
11. Heresztyn T, Worthley MI, Horowitz JD. Determination of L-arginine and NG, NG- and NG, NG=-dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 805: 325–329, 2004.
12. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol Renal Physiol 272: F561–F578, 1997.
13. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 33: 1013–1019, 1999.
14. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 56: 498–504, 2010.
15. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 138: 4713–4720, 1997.
16. Masini E, Cuzzocrea S, Mazzon E, Muia` C, Vannacci A, Fabrizi F, Bani D. Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol 148: 1124–1132, 2006.
17. McGuane JT, Debrah JE, Sautina L, Jarajapu YPR, Novak J, Rubin JP, Grant MB, Segal M, Conrad KP. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786–2796, 2011.
18. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 148: 671–677, 1987.
19. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 292: F330–F339, 2007.
20. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293: H3227–H3245, 2007.
21. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensininduced hypertension. Am J Physiol Regul Integr Comp Physiol 284: R893–R912, 2003.
22. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N()-nitro-L-arginine methyl ester hypertensive rats. Hypertension 58: 197–204, 2011.
23. Sasser JM, Moningka NC, Cunningham MW, Croker B, Baylis C. Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol 298: R740–R746, 2010.
24. Sasser JM, Sullivan JC, Elmarakby AA, Kemp BE, Pollock DM, Pollock JS. Reduced NOS3 phosphorylation mediates reduced NO/cGMP signaling in mesenteric arteries of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 43: 1080–1085, 2004.
25. Sasser JM. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 305: R559–R565, 2013.
26. Sütö T, Losonczy G, Qiu C, Hill C, Samsell L, Ruby J, Charon N, Venuto R, Baylis C. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 48: 1272–1277, 1995.
27. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 4: 41–51, 2003.
28. Szentiványi M, Zou AP, Mattson DL, Soares P, Moreno C, Roman RJ, Cowley AW. Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol 283: R266–R272, 2002.
29. Tain YL, Baylis C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int 72: 886–889, 2007.
30. Vásquez-Vivar J, Kalyanaraman B, Martásek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 37: 121–127, 2003.
31. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913–R935, 2005.
32. Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M, Kohsaka T, Yamamoto T, Ikegaya N. Relaxin ameliorates saltsensitive hypertension and renal fibrosis. Nephrol Dial Transplant 27: 2190–2197, 2012.
33. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 20: 604–612, 2009.